Early Integrated Supportive Care Study for Gastrointestinal Cancer Patients
1 other identifier
interventional
176
1 country
1
Brief Summary
Currently at the BC Cancer Agency, oncologists decide when to refer a patient to the Pain and Symptom Management/Palliative Care (PSMPC) team, and their decisions are made subjectively and without standard guidelines/symptom assessment tools. Patients are often referred late in their treatment. The PSMPC team sees patients in their own clinic, separately from the oncologists, and do not often collaborate in a patient's care. Early integration of palliative care into oncological care has been shown to improve quality of life and to prolong survival, as well as to reduce inappropriately aggressive oncological care at end of life, and reduce costs of care. We will test an early oncology-integrated palliative care model, with the aims of determining whether 1) the introduction of PSMPC support at the time of diagnosis leads to better symptom management and quality of life of patients, 2) early integration of palliative care into medical oncology care reduces aggressiveness of cancer treatment near end of life, and 3) a fully integrated service delivery model is sustainable.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable cancer
Started Feb 2015
Longer than P75 for not_applicable cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 7, 2015
CompletedFirst Posted
Study publicly available on registry
January 12, 2015
CompletedStudy Start
First participant enrolled
February 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2019
CompletedJanuary 27, 2020
January 1, 2020
3.8 years
January 7, 2015
January 23, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Total symptom distress score
Total symptom distress score will be measured using a modified Edmonton Symptom Assessment System (ESAS). Individual patient scores at 4 months will be compared to their scores at recruitment (first oncology appointment).
4 months after recruitment
Secondary Outcomes (3)
Use of health services
4 months after recruitment
Aggressiveness of cancer treatment
4 months after recruitment
Details of death (survival time from first oncology appointment at BC Cancer location of death (home, hospice, Cancer Centre)
1 year from recruitment
Study Arms (2)
Early Palliative Care
ACTIVE COMPARATORDuring their first oncology appointment, the intervention arm patients will self-report any symptoms related to their cancer or treatment to the study team; scores at or above a defined benchmark will be seen by Pain and Symptom Management/Palliative Care team members during or immediately after their oncology appointment. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
Standard Care
NO INTERVENTIONDuring their first oncology appointment, the control arm patients will self-report any symptoms related to their cancer or treatment to the study team; self-reports will be collected but not shared with the Pain and Symptom Management/Palliative Care team, and patients will continue with their oncology appointment as per standard procedure. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
Interventions
Eligibility Criteria
You may qualify if:
- diagnosed with a gastrointestinal (GI) cancer
- have appointments in GI clinic during study days
- able to complete a symptom assessment form on their own or with the help of a family member or interpreter
You may not qualify if:
- already receiving care from the Pain and Symptom Management/Palliative Care team
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pippa Hawleylead
Study Sites (1)
British Columbia Cancer Agency - Vancouver Centre
Vancouver, British Columbia, V5Z 4E6, Canada
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Philippa Hawley, B.Med
British Columbia Cancer Agency
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Head Palliative Care Physician
Study Record Dates
First Submitted
January 7, 2015
First Posted
January 12, 2015
Study Start
February 1, 2015
Primary Completion
December 1, 2018
Study Completion
April 1, 2019
Last Updated
January 27, 2020
Record last verified: 2020-01
Data Sharing
- IPD Sharing
- Will not share